WASHINGTON — Cardiac markers, employed in diagnosis and prognosis for acute coronary syndromes both in central laboratories as well as at the point of care, have represented one of the most rapidly growing segments of the clinical diagnostics market over the past few years. The primary role at present for cardiac markers such as Troponin, creatine kinase-MB (CKMB) and myoglobin is in diagnosis of acute coronary syndromes, but there is growing interest in newer markers that can aid in assessing the risk for myocardial infarction, such as markers of unstable coronary plaque, as well as in stroke markers for initial diagnosis and risk assessment. (Cardiovascular Devices & Drugs)